Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius(Heidelberg University), Frank Stegelmann(University Hospital Ulm), Karsten Spiekermann(German Cancer Research Center), Susanne Saußele(University of Mannheim), Michael Pfreundschuh(Saarland University), Rüdiger Hehlmann(Heidelberg University), Hermann Einsele(Universitätsklinikum Würzburg), Juliana Schwaab(Heidelberg University), Andreas Reiter(Heidelberg University), Claudia Haferlach(Munich Leukemia Laboratory (Germany)), Martine Jotterand(University Hospital of Lausanne), Brigitte Schlegelberger(Heidelberg University), Andreas Hochhaus(Jena University Hospital), Benjamin Hanfstein(Heidelberg University), Christiane Falge(Nuremberg Hospital), Andreas Neubauer(RWTH Aachen University), Susanne Jung-Munkwitz(Universität Hamburg), Cornelius F. Waller(University Medical Center Freiburg), Michael Kneba(Universitäts Hautklinik Kiel), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Anthony D. Ho(Heidelberg University), Michael Lauseker(Zimmer Biomet (Germany)), Armin Leitner(Universität Hamburg), Gudrun Göhring(Medizinische Hochschule Hannover), Gabriela M. Baerlocher(Terry Fox Research Institute), Joerg Hasford(Ludwig-Maximilians-Universität München), Ulrike Proetel(Heidelberg University), Martin C. Müller(Universität Hamburg), Lothar Kanz(University of Freiburg), Wolf‐Karsten Hofmann(Heidelberg University), Jörg Schubert(Saarland University)
Cited by 289
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k